您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Cyclophosphamide monohydrate
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Cyclophosphamide monohydrate
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Cyclophosphamide monohydrate图片
CAS NO:6055-19-2
包装与价格:
包装价格(元)
10mM (in 1mL DMSO)电议
50mg电议
5g电议
10g电议

产品介绍
环磷酰胺一水合物是一种合成烷化剂,化学性质与氮芥有关,具有抗肿瘤和免疫抑制活性。
Cas No.6055-19-2
别名环磷酰胺水合物; Cyclophosphamide monohydrate
化学名N,N-bis(2-chloroethyl)-2-oxo-1,3,2λ5-oxazaphosphinan-2-amine;hydrate
Canonical SMILESC1CNP(=O)(OC1)N(CCCl)CCCl.O
分子式C7H15Cl2N2O2P.H2O
分子量279.1
溶解度≥ 13.95 mg/mL in DMSO, ≥ 96 mg/mL in EtOH, ≥ 51.5 mg/mL in Water with ultrasonic and warming
储存条件Store at -20°C,unstable in solution, ready to use.
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

IC50: 511 μM for AChE

Cyclophosphamide monohydrate is used in the cancer treatment in children. As a prodrug it should be metabolized by cytochrome P-450 enzymes to produce the active alkylating species, which are responsible for its cytotoxic effects.

In vitro: Cyclophosphamide inhibited the AChE reversibly with an IC50 of 511 μM. In the control system, Km was 132 μM for AChE, which increased by 78% in the CP treated system. The nature of cyclophosphamide was of the linear mixed type (partially competitive and purely noncompetitive). The values of Ki and KI were estimated to be 378 and 582 μM respectively, indicating that noncompetitive inhibition was predominant over competitive [1].

In vivo: PK studies in mice revealed a delayed plasma clearance of cyclophosphamide after carbon-tetrachloride pretreatment. Plasma levels of total alkylating activity and 4-hydroxycyclophosphamide increased more slowly and reached a lower peak. However, there was no difference in the AUC for either plasma total alkylating activity or plasma 4-hydroxycyclophosphamide between two groups. Thus, prolonged exposure of tumor cells to 4-hydroxycyclophosphamide might be responsible for the increased antitumor activity of cyclophosphamide following carbon-tetrachloride pretreatment [2].

Clinical trial: Twenty-two children not receiving other therapy known to influence drug metabolism were selected, of whom, nine were receiving combination treatment and thirteen were identified as controls. Results showed that the the plasma cyclophosphamide clearance was lower in patients receiving fluconazole combined group [3].

References:
[1] al-Jafari AA,Duhaiman AS,Kamal MA.  Inhibition of human acetylcholinesterase by cyclophosphamide. Toxicology.1995 Jan 19;96(1):1-6.
[2] Harris RN,Basseches PJ,Appel PL,Durski AM,Powis G.  Carbon tetrachloride-induced increase in the antitumor activity of cyclophosphamide in mice: a pharmacokinetic study. Cancer Chemother Pharmacol.1984;12(3):167-72.
[3] Yule SM,Walker D,Cole M,McSorley L,Cholerton S,Daly AK,Pearson AD,Boddy AV.  The effect of fluconazole on cyclophosphamide metabolism in children. Drug Metab Dispos.1999 Mar;27(3):417-21.